Home | My Account | Online Store | Contact & Demand | Press Room | About Us | FAQs
Home
Buy & Subscribe
Special Features
Products & Services
Online Store
Products by category
Products by publisher
Product lines
News Channels
Biotechnology
Therapeutic Areas
Business
RSS Feeds
Free RSS News
Get the latest news direct
to your desktop
feed image

Search in our News Channels

  

Search in our Online Store
Antibodies
Filter     Order     Display # 
Date Item Title Hits
01 Sep 2010 Agensys, an Affiliate of Astellas, Announces Initiation of Phase I Clinical Trial of AGS-16M8F for Renal Cancer 26
31 Aug 2010 BTG plc (BGC.L) Signs $16.6 Mln Deal To Sell Nycomed's Antivenom Drugs 51
30 Aug 2010 MedImmune receives complete response letter on motavizumab 80
27 Aug 2010 Genentech Receives Refuse to File Letter from FDA for T-DM1 60
19 Aug 2010 Human Genome Sciences and GlaxoSmithKline Announce FDA Priority Review Designation for BENLYSTA (belimumab) as a Potential Treatment for Systemic Lupus Erythematosus 135
18 Aug 2010 Ipilimumab Receives FDA Priority Review Designation for Adult Patients with Previously Treated Advanced Melanoma 80
16 Aug 2010 Morphotek, Inc. Announces Initiation of a Phase I Study for MORAb-028, an IgM-Type Monoclonal Antibody, in Patients with Advanced Melanoma 68
13 Aug 2010 NICE concludes omalizumab is not an effective use of NHS resources for children under 12 114
11 Aug 2010 Amgen Announces Top-Line Results of Phase 3 Head and Neck Cancer Trial 101
11 Aug 2010 Biotest AG: Development of BT-062 makes further progress with start of a new clinical trial 130
10 Aug 2010 Centocor Ortho Biotech Inc.: STELARA(R) Three-Year Efficacy and Safety Data Presented on Patients with Moderate to Severe Plaque Psoriasis 96
10 Aug 2010 Genmab Announces Top-Line Interim Results for Ofatumumab in Diffuse Large B-Cell Lymphoma 81
10 Aug 2010 MabVax Therapeutics Receives $1.1 Million Phase 2 Small Business Technology Transfer Program Award From The National Cancer Institute 72
10 Aug 2010 Scancell Signs Antibody Licence Agreement with Cancer Research Technology 58
10 Aug 2010 Immunomodulatory antibody BT-061 shows competitive efficacy in the indication Rheumatoid Arthritis 140
09 Aug 2010 GSK and Genmab Announce Topline Results from the Concluded Pivotal Trial of Arzerra (Ofatumumab) in Fludarabine and Alemtuzumab Refractory Chronic Lymphocytic Leukemia 43
04 Aug 2010 Clinical Phase I Results of GANYMED's iMAB362 Antibody Demonstrate Excellent Safety 78
04 Aug 2010 Glycotope Received Regulatory Approval for Glycooptimized and Fully Human Glycosylated Antibody CetuGEX and Enrolls First Patients in Clinical Trial 67
04 Aug 2010 Elusys Awarded Additional $40.6 Million Under Existing U.S. Government Contract to Fund Advanced Development of Anthim, a New Treatment for Anthrax 52
04 Aug 2010 ACTEMRA Humanized Anti-Human IL-6 Receptor Monoclonal Antibody 74
03 Aug 2010 Seattle Genetics Expands Antibody-Drug Conjugate Collaboration with Genentech 74
02 Aug 2010 MorphoSys Announces Clinical Milestone from Strategic Alliance 67
29 Jul 2010 Anthera Initiates Expanded and Extended PEARL-SC Phase 2b Clinical Study in Lupus With A-623 - A Subcutaneous Dual Inhibitor of Membrane and Soluble B-Cell Activating Factor (BAFF or BLyS) 108
28 Jul 2010 Astellas to Pay $295 Million to Extend License of Regeneron's VelocImmune Antibody Technology through 2023 25
26 Jul 2010 NovImmune Enters Exclusive Antibody Licensing Agreement with Genentech 96
22 Jul 2010 Merrimack Pharmaceuticals and sanofi-aventis Initiate Enrollment in a Phase 2 Combination Study of MM-121 and exemestane in Breast Cancer 155
21 Jul 2010 Genentech Provides Update from Avastin FDA Advisory Committee Meeting 114
20 Jul 2010 Seattle Genetics and Agensys, an Affiliate of Astellas, Announce Initiation of Phase I Clinical Trial of ASG-5ME for Pancreatic Cancer 77
20 Jul 2010 Pfizer Suspends Chronic Pain Studies in Tanezumab Clinical Trial Program; Some Studies Continue in Areas of Unmet Medical Need 79
19 Jul 2010 Amgen gets rapid FDA review for denosumab 85
 
<< Start < Prev 1 2 3 4 5 6 7 8 9 10 Next > End >>
Results 1 - 30 of 1861

PipelineReview.com is powered by La Merie Business Intelligence La Merie Business Intelligence

For immediate assistance, please call us during business hours: Mon-Fri 09:00am - 18:30pm; GMT+01

La Merie S.L | Passatge Jordi Ferran, 20 | E-08028 Barcelona | T +34 93 342 91 97 | F +34 93 342 91 98 | Email info@lamerie.com | Internet www.lamerie.com
All contents © by La Merie S. L

Competitor Analysis Series

Tau and Amyloid Beta Targeted Therapy of Alzheimer’s Disease

Order Now

Recommended Report

R&D Drug Pipeline Database
Order Now

Subscribe La Merie Biologics